Literature DB >> 26503845

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer.

Anna Wójcicka1, Monika Kolanowska1, Krystian Jażdżewski2.   

Abstract

MicroRNAs, short non-coding regulators of the gene expression, are subjects of numerous investigations assessing their potential use in the diagnostics and management of human diseases. In this review, we focus on studies that analyze the utility of microRNAs as novel diagnostic and therapeutic tools in follicular cell-derived thyroid carcinomas. This very interesting and promising field brings new insight into future strategies for personalized medicine.
© 2016 European Society of Endocrinology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26503845     DOI： 10.1530/EJE-15-0647

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


  18 in total

1.  Search for New Target Genes of MicroRNA for Differential Diagnosis of Benign and Malignant Neoplasms of the Thyroid Gland by In Silico Methods.

Authors:  V V Kononchuk; E V Kopeikina; T S Kalinina; O V Saik; E Yu Alekseenok; M K Kolyagina; V A Matashova; S P Shevchenko; L F Gulyaeva; N E Kushlinskii
Journal:  Bull Exp Biol Med       Date:  2022-06-23       Impact factor: 0.804

2.  Hypermethylation of microRNA-497-3p contributes to progression of thyroid cancer through activation of PAK1/β-catenin.

Authors:  Yuxia Fan; Xin Fan; Hao Yan; Zheng Liu; Xiaoming Wang; Qingling Yuan; Jie Xie; Xiubo Lu; Yang Yang
Journal:  Cell Biol Toxicol       Date:  2022-01-23       Impact factor: 6.691

Review 3.  miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Authors:  Emanuela Minna; Paola Romeo; Matteo Dugo; Loris De Cecco; Katia Todoerti; Silvana Pilotti; Federica Perrone; Ettore Seregni; Luca Agnelli; Antonino Neri; Angela Greco; Maria Grazia Borrello
Journal:  Oncotarget       Date:  2016-03-15

Review 4.  miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers.

Authors:  Manuel Saiselet; Jaime M Pita; Alice Augenlicht; Geneviève Dom; Maxime Tarabichi; Danai Fimereli; Jacques E Dumont; Vincent Detours; Carine Maenhaut
Journal:  Oncotarget       Date:  2016-08-09

5.  Association of microRNA-related gene XPO5 rs11077 polymorphism with susceptibility to thyroid cancer.

Authors:  Jing Wen; Qingjun Gao; Nanpeng Wang; Wei Zhang; Kun Cao; Qiang Zhang; Shi Chen; Lixin Shi
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy.

Authors:  Łukasz Koperski; Marta Kotlarek; Michał Świerniak; Monika Kolanowska; Anna Kubiak; Barbara Górnicka; Krystian Jażdżewski; Anna Wójcicka
Journal:  Oncotarget       Date:  2017-07-25

7.  Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer.

Authors:  Nur Selvi Gunel; Nihal Birden; Cansu Caliskan Kurt; Bakiye Goker Bagca; Behrouz Shademan; Fatma Sogutlu; Neslihan Pinar Ozates; Cigir Biray Avci
Journal:  Mol Biol Rep       Date:  2021-08-10       Impact factor: 2.316

8.  MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.

Authors:  Wojciech Gierlikowski; Katarzyna Broniarek; Łukasz Cheda; Zbigniew Rogulski; Marta Kotlarek-Łysakowska
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

Review 9.  miRNAs Signature in Head and Neck Squamous Cell Carcinoma Metastasis: A Literature Review.

Authors:  Soussan Irani
Journal:  J Dent (Shiraz)       Date:  2016-06

10.  Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.

Authors:  Isabella Maria Dias Payão Ortiz; Mateus Camargo Barros-Filho; Mariana Bisarro Dos Reis; Caroline Moraes Beltrami; Fabio Albuquerque Marchi; Hellen Kuasne; Luísa Matos do Canto; Julia Bette Homem de Mello; Cecilie Abildgaard; Clóvis Antônio Lopes Pinto; Luiz Paulo Kowalski; Silvia Regina Rogatto
Journal:  Clin Epigenetics       Date:  2018-11-20       Impact factor: 6.551
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.